Please ensure Javascript is enabled for purposes of website accessibility

Why NRx Pharmaceuticals Stock Vaulted Higher Today

By Keith Speights – Aug 23, 2021 at 3:53PM

Key Points

  • Israeli media reported that participants in a clinical study evaluating experimental COVID-19 vaccine BriLife were told they didn't need a third booster dose six months after receiving a second dose of the vaccine.
  • NRx owns the worldwide licensing rights to market BriLife.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors cheered reports in Israel that COVID-19 vaccine candidate BriLife appears to provide protection for at least six months after a second dose.

What happened

Shares of NRx Pharmaceuticals (NRXP 4.35%) were vaulting 15.1% higher as of 3:25 p.m. EDT on Monday. The nice gain came after Israeli media reported that participants in a clinical study evaluating experimental COVID-19 vaccine BriLife maintained a high level of protection six months after a second dose and didn't need a third booster dose. NRx owns exclusive global rights to market the BriLife vaccine, which was developed by the Israel Institute for Biological Research.

So what

NRx Pharmaceuticals has been one of the worst-performing vaccine stocks in 2021, with its shares sinking more than 50% as of the market close on Friday. It's not surprising that investors welcomed the news about the potentially long duration of protection for BriLife.

Gloved hands holding a syringe and a vaccine vial with an Israeli flag in the background.

Image source: Getty Images.

However, there are a few caveats with this good news. NRx didn't directly announce the results itself but instead referenced an article published in The Times of Israel. That article summarized a report that aired over the weekend on a television station in Israel, Channel 12. The Channel 12 story stated that 230 participants in the clinical study had been notified they didn't need a third dose of BriLife because their protection remained high but didn't provide many details.

The report that no third booster dose is needed six months after participants received a second dose is encouraging. However, it's still too early to claim victory for BriLife. More testing will be required.

Now what

Nrx Pharmaceuticals CEO Jonathan Javitt stated, "With this new information, and more expected in the coming weeks, we are preparing to submit a phase 2b/3 protocol for BriLife against an established active comparator." The company also awaits a decision by the U.S. Food and Drug Administration on Emergency Use Authorization for Zyesami in treating patients with severe COVID-19. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NRx Pharmaceuticals, Inc. Stock Quote
NRx Pharmaceuticals, Inc.
$1.44 (4.35%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.